Research Reports

Key takeaways

Net loss narrowed to $1,675,549 from $3,948,192 year-over-year due to $5.7 million unrealized warrant gain.

Operating expenses rose to $7.5 million from $6.0 million, driven by higher R&D spend of $4.9 million.

Cash and equivalents fell to $16,559,056 at March 31, 2026 from $22.1 million year-end amid $5.5 million net outflow.

Shareholders' equity increased to $5.5 million from $3.5 million, supported by warrant and option exercises netting $2.8 million.

Warrant derivative liability dropped to $9.3 million from $15.1 million following fair value gain.

Going concern doubt noted; additional financing needed for clinical trials and operations.

Full analysis

NervGen Pharma, a clinical-stage biotech focused on nervous system repair therapies like NVG-291 for spinal cord injury, reported improved Q1 2026 results with net loss halving to $1.7 million from $3.9 million prior year, primarily due to a larger $5.7 million unrealized gain on warrant derivatives versus $2.0 million last year. Operating expenses increased 25% to $7.5 million, reflecting elevated R&D at $4.9 million (up from $3.1 million) amid pre-revenue development of drug candidates. Cash burned $5.5 million, reducing balance to $16.6 million from $22.1 million at year-end, with financing inflows from warrant ($0.8 million net) and option exercises ($2.0 million net) providing support. Balance sheet shows warrant liability down to $9.3 million and positive equity of $5.5 million. Management flags material going concern uncertainty, dependent on additional capital for Phase 3 trials and operations, with no revenue expected soon.

NGEN · NervGen Pharma Corp. Common stock

Summary

Key takeaways

Full analysis